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Abstract
Congenital hyperinsulinism (CHI) causes dysregulated insulin secretion which can lead to life-threatening
hypoglycaemia if not effectively managed. CHI can be sub-classiﬁed into three distinct groups: diffuse, focal and
mosaic pancreatic disease. Whilst the underlying causes of diffuse and focal disease have been widely
characterised, the genetic basis of mosaic pancreatic disease is not known. To gain new insights into the underly-
ing disease processes of mosaic-CHI we studied the islet tissue histopathology derived from limited surgical re-
section from the tail of the pancreas in a patient with CHI. The underlying genetic aetiology was investigated
using a combination of high depth next-generation sequencing, microsatellite analysis and p57kip2 immuno-
staining. Histopathology of the pancreatic tissue conﬁrmed the presence of a deﬁned area associated with mar-
ked islet hypertrophy and a cytoarchitecture distinct from focal CHI but compatible with mosaic CHI localised to
a discrete region within the pancreas. Analysis of DNA extracted from the lesion identiﬁed a de novo mosaic
ABCC8 mutation and mosaic paternal uniparental disomy which were not present in leukocyte DNA or the sur-
rounding unaffected pancreatic tissue. This study provides the ﬁrst description of two independent disease-
causing somatic genetic events occurring within the pancreas of an individual with localised mosaic CHI. Our
ﬁndings increase knowledge of the genetic causes of islet disease and provide further insights into the underlying
developmental changes associated with β-cell expansion in CHI.
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Introduction
Congenital hyperinsulinism (CHI) is characterised by
dysregulated insulin secretion which can lead to life-
threatening hypoglycaemia. Patients who do not
respond to medical therapy may require a pancreatec-
tomy with the extent of the resection determined by
the genetic aetiology [1].
Three sub-classes of CHI exist, which are associ-
ated with distinct histological descriptions (see
below) and include diverse islet endocrine cell types
[1–3]. CHI is distinctly different from pancreatic
tumours such as insulinomas, which are derived
from expansion of insulin producing cells [4]. The
pathology of diffuse CHI (CHI-D) encompasses the
entire endocrine pancreas and can result from
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dominant or bi-allelic recessive mutations in one of
the known disease-causing genes. Islets in CHI-D
appear within the context of intact lobular architec-
ture and are associated with nucleomegaly in some
cells [2].
In contrast, focal CHI (CHI-F) occurs as a localised
region of adenomatous hyperplasia of abnormal β-cells
with limited clonal expansion but without neoplastic
transformation. In CHI-F unmasking of a paternally
inherited recessively acting ABCC8/KCNJ11 mutation
and the concurrent loss of an imprinted region by
paternal uniparental disomy (UPD) upstream of the
genes confers a growth advantage to the cell leading to
the development of a focal lesion which over-secretes
insulin [5,6]. Unlike pancreatic tumours such as
insulinomas, focal CHI lesions also contain glucagon-,
somatostatin-, and pancreatic polypeptide-secreting
cells [3,4].
More rarely, mosaic histology is described where
there are hyperplastic islets, often in a discrete lobe of
the pancreas with shrunken/condensed islets existing
outside the affected lobular region [3]. Mosaic CHI
differs from that of the focal disease because of the
absence of adenomatous hyperplasia. The presence of
Localised Islet Nuclear Enlargement (LINE) within the
affected lobe of the pancreas can also signify mosai-
cism [3,7]. The underlying genetic cause(s) of mosaic-
CHI are unknown.
Figure 1. Lobular organisation of mosaic CHI. (A) 18F-DOPA PET-CT image scans reveal a discrete area with high uptake of tracer in the
tail of the pancreas, indicated by the arrows in both superimposed PET/CT (left) and maximum intensity projection images (right).
(B) Different parts of the resected pancreas stained for immunoreactivity to insulin. Note the abnormally high level of insulin-producing
cells localised only to a particular region of the pancreas which is not observed elsewhere. Scale bar, 2 mm. (C) H&E and insulin (Ins+)
immunohistochemistry to compared islets from the healthy part of the pancreas (upper images, white arrows in the H&E ﬁgure) with
those from the unaffected regions (lower images, black arrows in the H&E ﬁgure). The most noticeable pathological feature of the islets
from within the affected region is hyperplasia leading to a marked increase in size and structure. Scale bars; H&E 100 μm: insulin
50 μm. (D) Quantitative analysis of abnormal islets compared to tissue controls, diffuse CHI islets (n = 6 cases) and control human islets
(n = 12 cases). Note how abnormal islets have signiﬁcantly increased surface areas and islet cell numbers, p < 0.0001.
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We describe the genetic and histopathological ﬁnd-
ings of a case with mosaic-CHI, providing new
insights into the disease mechanisms of this disorder.
Materials and methods
The female proband was born at 39 weeks gestation
with a birth weight of 4.01 kg to unaffected, non-
consanguineous parents. She developed hypoglycaemic
seizures within 24 h of birth requiring 15% dextrose and
glucagon infusion. CHI was conﬁrmed (plasma glucose
1.1 mmol/l [19.8 mg/dl], insulin 224 pmol/l) and
glycaemic control was achieved with partial response to
diazoxide (15 mg/kg/day), followed by second line treat-
ment with Octreotide (30 mcg/kg/day). Syndromic cau-
ses of hyperinsulinism were excluded by clinical genetic
review. As the frequency of hypoglycaemia increased, at
2.7 years the patient underwent 18FDOPA PET-CT
scanning which identiﬁed a focus of increased isotope
activity. As the patient was only partially responsive to
treatment with diazoxide and required high dose
Octreotide by subcutaneous injections with signiﬁcant
risk of side effects, partial pancreatic surgery was con-
sidered as the therapy of choice. The lesion within a
pancreatic lobule was removed by laparoscopic surgery
which effected cure. The patient underwent a fast fol-
lowing pancreatectomy with adequate ketogenesis and
absence of hypoglycaemia. Pre-feed plasma glucose was
tested by home glucose monitoring for 6 months after
surgery; no episodes of hypoglycaemia were recorded.
There have been no concerns regarding clinical suspi-
cion of hypoglycaemia 1 year after surgery.
The study was conducted in accordance with the
Declaration of Helsinki with informed consent obtained
from the parents (REC 07/H1010/88).
Histopathology
H&E staining was used to exclude insulinoma as a
cause for hyperinsulinism. Immunohistochemistry for
insulin, glucagon, somatostatin and p57kip2 expression
was performed on formalin-ﬁxed parafﬁn-embedded
(FFPE) pancreatic tissue as described previously [8].
Comparative quantiﬁcation of islets was performed
using tissues from CHI-F (n = 12), CHI-D (n = 6) and
healthy controls (n = 4) [8].
Genetics
Targeted next generation sequencing of 14 genes,
(ABCC8, KCNJ11, GLUD1, HADH, GCK, HNF4A,
HNF1A, SLC16A1, CACNA1D, KDM6A, KMT2D,
PMM2, INSR1, TRMT10A) known to cause isolated or
syndromic CHI was undertaken using DNA extracted
from the patient’s leukocytes and FFPE pancreatic tis-
sue excised from the lesion and surrounding normal tis-
sue [9]. Coding mutations in the MEN1 gene were
excluded by Sanger sequencing of leukocyte DNA.
Following the identiﬁcation of a mutation, Sanger
sequencing of ABCC8 exon 37 (NM_001287174.1)
was performed on leukocyte and buccal cell DNA
from the patient and leukocyte DNA from the par-
ents [10].
Loss-of-heterozygosity was investigated by analysis
of 12 microsatellites spanning Chr11p15 using DNA
extracted from the pancreatic lesion, surrounding nor-
mal tissue and leukocytes from the patient and parents
as previously described [10].
Figure 2. Proﬁle of islet hormones and p57kip2 expression in CHI
tissues. (A) The expression of insulin (Ins+), glucagon (Glu+),
somatostatin (Sst+) and pancreatic polypeptide (PP+) in islet cells
from the affected region of the pancreas, scale bar 200 μm.
(B) Representative images of islet (indicated by the dotted
regions) p57kip2 expression in the mosaic tissue from both the
control and affected regions (scale bar, 50 μm). (C) Quantitative
expression of p57kip2 in islet cells from the mosaic tissue
(affected and control regions) compared to focal CHI lesions
(n = 12 cases) and diffuse islets (n = 6 cases).
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Results
Mosaic-CHI islet proﬁle and LINE
18F-DOPA PET-CT scanning revealed the presence
of a single 22.5 mm2 area of hyperactive tissue within
the pancreas (Figure 1A). Histological analysis dem-
onstrated abnormal tissue architecture conﬁned to a lob-
ule (Figure 1B). Unlike most CHI-F tissues, islet cells
were not enriched and localised to a discrete anatomical
region or focus circumscribed by a well-deﬁned cap-
sule, but instead were interspersed with exocrine com-
ponents (Figure 1C). The distribution of exocrine and
endocrine tissues was suggestive of mosaic CHI.
The islets expressed insulin, glucagon, somatostatin
and pancreatic polypeptide, indicating the diversity of dif-
ferent endocrine cells without preferential insulin enrich-
ment in contrast to CHI-F tissue (Figure 2A). The
presence of other islet endocrine cells also excluded
insulinoma as a possible cause of disease [4]. Islet surface
area was 4.8-fold larger than age-matched control islets
and islets from CHI-D tissue, p < 0.0001 (Figure 1D),
indicating a clear distinction from CHI-D. The histology
was typical of mosaic CHI with affected islets being
irregular in shape, hyperplastic and containing more cells
than controls or CHI-D islets (p < 0.0001) (Figure 1D).
In contrast, islets outside the lobule were shrunken com-
pared to controls (p < 0.0001) and contained fewer cells
(p < 0.0001) (Figure 1D). Mosaic islets contained numer-
ous cells with enlarged nuclei (average nuclear surface
area 71.4  4 μm2 [n = 201 cells], p < 0.001) which
were signiﬁcantly larger than control islet cells
(34  4 μm2 [n = 195]) but smaller than islet cells from
CHI-D with nucleomegaly (115  5.3 μm2 [n = 103]).
These criteria, and the appearance of shrunken cells with
dense nuclear crowding in islet cells from outside the
affected region (Figure 1C), are consistent with previous
descriptions of LINE and mosaic CHI disease [3].
Loss of p57Kip2 expression
p57kip2 staining demonstrated clear nuclear reactivity in
28–31% of surface islet cells from control or CHI-D tissue,
but not in islet cells examined within the impaired lobular
domain (Figure 2B,C). This suggests that, in mosaic-CHI,
as with CHI-F, impaired expression of the cell cycle
repressor p57kip2 correlates with abnormal islet cell devel-
opment leading to inappropriate β-cell expansion.
Two post-zygotic genetic events within the lesion
Microsatellite analysis showed mosaic maternal loss-
of-heterozygosity (with an average maternal peak
height reduction of 27%) (see supplementary material,
Figure S1) conﬁned to the affected pancreatic tissue
which spanned a minimal region of 3.1 Mb
(Chr11:1,445,456-17,567,129), extending across the
differentially methylated region and ABCC8. Dosage
analysis was consistent with loss-of-heterozygosity
resulting from UPD rather than a deletion.
Targeted next-generation sequencing, followed by con-
ﬁrmatory Sanger sequencing, identiﬁed a mosaic p.
(Glu1507Lys); c.4519G>A, ABCC8 variant (119/419
reads [28%]) in the affected tissue (see supplementary
material, Figure S1). This variant was not called in the
normal pancreatic tissue, buccal cell DNA nor the periph-
eral leukocytes of the patient and parents. It was not pos-
sible to deduce whether the p.(Glu1507Lys) variant had
arisen on the maternal or paternal chromosome as no
informative variants were detected on sequencing which
would have allowed for the mutation to be phased.
Discussion
Early identiﬁcation of the underlying pathobiology of
CHI is crucial for guiding treatment at an early stage.
Although there are key diagnostic criteria for CHI-D
and CHI-F, up to 10% of cases have atypical histology
which have been variably described as mosaic CHI or
LINE. An understanding of the pathology in such cases
is limited by the variability in phenotype and infrequent
access to pancreatic tissue. Here, we have identiﬁed a
novel genetic cause of CHI in a patient who has the
typical histological features of mosaic CHI [3].
The islet hypertrophy and cytoarchitecture observed in
mosaic CHI is distinct from that of CHI-F where loss of
p57kip2 leads to β-cell hyperplasia and the formation of a
discrete mass of islet cells, often contained within a cap-
sule demarcating the lesion [11]. In mosaic CHI, hyper-
plastic islets are constrained to a lobe of the pancreas
where they appear enlarged in size when compared to
islets outside the affected lobule(s) [3]. These criteria were
observed within the affected pancreatic lobule in our
patient, alongside the presence of shrunken islets with
nuclear crowding outside the lesion, typifying the diagno-
sis of mosaic CHI. This histopathological description is
also compatible with LINE [3,7], where nuclear enlarge-
ment is considerably smaller than irregular nucleomegaly
observed in patients with diffuse CHI [8].
Whilst the organisation of islets in mosaic CHI patients
is distinct from CHI-D and CHI-F, the underlying genetic
cause(s) of disease have remained unknown. Here, we
report how islet mosaicism resulted from a mosaic
ABCC8 mutation, p.(Glu1507Lys), which is reported as
dominantly acting [12], together with mosaic paternal
UPD of chromosome 11p15 within the pancreatic lesion.
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Whilst the underlying genetic aetiology in our
patient is similar to that described in CHI-F, whereby
paternal UPD unmasks a recessively acting germline
or somatic mutation [13], to our knowledge two inde-
pendent somatic events isolated to the pancreatic tissue
have not been reported in patients with CHI to date.
Furthermore, a difference between the genetics in our
case and CHI-F is the presence of a dominant, rather
than recessively acting, K-ATP channel mutation. As
heterozygosity for the p.(Glu1507Lys) mutation is suf-
ﬁcient to cause over-secretion of insulin from the
β-cell, and given that the parent of origin for the chro-
mosome harbouring the mutation was not determined,
it has not been possible to deduce the temporal
sequence of genetic events and how this has contrib-
uted to abnormal tissue expansion. If the mutation had
arisen on the paternal chromosome it is possible that it
was present in cells outside the lesion but at a level below
our limit of detection (i.e. <2% using a mosaic variant
caller for targeted next generation sequencing of DNA
from leukocytes and unaffected pancreas and <10% for
Sanger sequencing of buccal DNA) which only became
detectable following a UPD event within the lesion.
Whilst we report a novel aetiology for mosaic histo-
logical disease, given the heterogeneous nature of this
condition it is possible that other genetic mechanisms
for mosaic CHI exist. Based on our ﬁndings we rec-
ommend in-depth molecular genetic testing of DNA
extracted from affected pancreatic tissue as a way of
identifying novel disease-causing mechanisms of CHI.
In conclusion, we describe two disease-causing
somatic events within the pancreas of an individual
with CHI and illustrate how studying pancreatic DNA
is crucial for improving knowledge on the underlying
mechanisms of mosaic-CHI.
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